Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us ...

Zealand Pharma shares fell about 4% in Thursday trading after new Phase 2 results for its Roche-partnered obesity drug petrelintide showed encouraging weight loss but a modest improvement in blood ...

Swiss biotech ADC Therapeutics has secured an $86.6 million (€77.5 million) financing agreement alongside debt and royalty ...

Roche has partnered with China’s Defand Therapeutics to discover molecular glue degraders for cancer and immune diseases, in a research and licensing agreement reportedly worth close to $1 billion ...

Paris-based Rivercell has raised $25 million (about €22 million) in seed funding to generate experimental data and build AI ...

Dutch life sciences investor Forbion has raised €2.3 billion across two new funds to finance about 30 biotech companies, ...

Oxford-based Sensible Biotechnologies has secured a $47 million (€42 million) financing package to scale a platform that ...

France’s WhiteLab Genomics has raised $26 million (€23 million) in Series B financing to expand experimental validation of ...

Genmab and AbbVie's bispecific antibody epcoritamab, added to R-CHOP chemoimmunotherapy, cut the risk of progression or death by 51% in a Phase 3 trial in newly diagnosed diffuse large B-cell lymphoma ...

Boehringer Ingelheim’s survodutide delivered average weight loss of up to 13.1% in a Phase 3 trial involving people with ...

Australian biopharma company CSL has entered an exclusive global partnership with Basel-based Alentis Therapeutics to ...

Genmab’s rinatabart sesutecan (Rina-S) delivered durable responses in a Phase 2 trial in platinum-resistant ovarian cancer, providing encouraging validation for the centerpiece of its $1.8 billion ...